X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
copanlisib (30) 30
index medicus (21) 21
oncology (13) 13
humans (11) 11
idelalisib (11) 11
cancer (9) 9
pharmacology & pharmacy (9) 9
follicular lymphoma (7) 7
bay 80-6946 (6) 6
pathway (6) 6
pi3k (6) 6
1-phosphatidylinositol 3-kinase (5) 5
animals (5) 5
class i phosphatidylinositol 3-kinases - antagonists & inhibitors (5) 5
duvelisib (5) 5
ibrutinib (5) 5
lymphoma (5) 5
tumors (5) 5
antineoplastic agents (4) 4
antineoplastic agents - pharmacology (4) 4
antineoplastic agents - therapeutic use (4) 4
chemotherapy (4) 4
chronic lymphocytic-leukemia (4) 4
gemcitabine (4) 4
hematology (4) 4
hemic and lymphatic diseases (4) 4
lymphomas (4) 4
male (4) 4
middle aged (4) 4
neoplasms - drug therapy (4) 4
open-label (4) 4
original (4) 4
phosphatidylinositol 3-kinases - antagonists & inhibitors (4) 4
pi3k inhibitor (4) 4
pyrimidines - pharmacokinetics (4) 4
quinazolines - pharmacokinetics (4) 4
solid tumors (4) 4
acalabrutinib (3) 3
aged (3) 3
apoptosis (3) 3
cell line, tumor (3) 3
drug approval (3) 3
enzyme inhibitors - administration & dosage (3) 3
enzyme inhibitors - adverse effects (3) 3
female (3) 3
hyperglycemia (3) 3
kinases (3) 3
lenalidomide (3) 3
mutation (3) 3
p110-alpha (3) 3
pharmacokinetics (3) 3
pharmacology (3) 3
phase-i (3) 3
phase-ii trial (3) 3
pyrimidines - therapeutic use (3) 3
quinazolines - therapeutic use (3) 3
t cells (3) 3
1st-in-human phase-i (2) 2
administration, intravenous (2) 2
adult (2) 2
akt protein (2) 2
analysis (2) 2
angiogenesis inhibitors (2) 2
antimitotic agents (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
argx-110 (2) 2
article (2) 2
b-cell lymphoma (2) 2
b-cell receptor (2) 2
bay-80-6946 (2) 2
biochemistry & molecular biology (2) 2
biological products (2) 2
bortezomib (2) 2
brentuximab vedotin (2) 2
cancer research (2) 2
care and treatment (2) 2
cell proliferation (2) 2
chemistry, medicinal (2) 2
chronic lymphocytic leukemia (2) 2
diagnosis (2) 2
discovery (2) 2
dlbcl (2) 2
drug resistance (2) 2
enzyme inhibitors - pharmacology (2) 2
gene expression (2) 2
human (2) 2
hypertension (2) 2
imidazoles - pharmacology (2) 2
indolent non-hodgkin lymphoma (2) 2
inhibitor (2) 2
inhibitors (2) 2
intravenous pi3k inhibitor (2) 2
lymphoma, non-hodgkin - drug therapy (2) 2
lymphoma, non-hodgkin - pathology (2) 2
management (2) 2
medical prognosis (2) 2
medicine (2) 2
medicine & public health (2) 2
metabolism (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 2017, Volume 28, Issue 9, pp. 2169 - 2178
Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the a-and delta-isoforms. Patients and... 
Malignant lymphoma | Copanlisib | Treatment | PI3K inhibitor | treatment | DLBCL | EFFICACY | NON-HODGKINS-LYMPHOMAS | IBRUTINIB | BAY 80-6946 | INTERNATIONAL WORKSHOP | PI3K-DELTA | ONCOLOGY | copanlisib | MANTLE CELL LYMPHOMA | IDELALISIB | CHRONIC LYMPHOCYTIC-LEUKEMIA | malignant lymphoma | Original | Editor's Choice
Journal Article
Chinese Journal of New Drugs, ISSN 1003-3734, 12/2018, Volume 27, Issue 24, pp. 2869 - 2872
Journal Article
Oncotarget, ISSN 1949-2553, 09/2018, Volume 9, Issue 75, pp. 34103 - 34121
Despite the recent advances in the treatment of ovarian cancer, it remains an area of high unmet medical need. Epithelial ovarian cancer is associated with... 
Mesothelin | Copanlisib | Anetumab ravtansine | Antibody-drug conjugate | Ovarian cancer
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 03/2019, Volume 19, Issue 3, pp. 135 - 141
Copanlisib is a phosphoinositol 3-kinase (PI3K) inhibitor approved for the third-line treatment of follicular non-Hodgkin lymphoma. Although the drug is... 
Hypertension | Follicular lymphoma | Hyperglycemia | Copanlisib | PI3K | PI3K-DELTA | ONCOLOGY | INHIBITOR | HEMATOLOGY
Journal Article
BLOOD, ISSN 0006-4971, 04/2019, Volume 133, Issue 16, pp. 1742 - 1752
This phase 1/2 study assessed parsaclisib (INCB050465), a next-generation, potent, and highly selective phosphatidylinositol 3-kinase delta (PI3K delta)... 
CLINICAL-PRACTICE GUIDELINES | DIAGNOSIS | P110-ALPHA | MANAGEMENT | IDELALISIB | RESPONSE ASSESSMENT | CHRONIC LYMPHOCYTIC-LEUKEMIA | HODGKIN | FOLLICULAR LYMPHOMA | COPANLISIB | HEMATOLOGY | Lymphoid Neoplasia
Journal Article
Annals of oncology : official journal of the European Society for Medical Oncology, ISSN 0923-7534, 2016, Volume 27, Issue 10, pp. 1928 - 1940
Journal Article
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 12/2019, Volume 27, Issue 23, p. 115150
A concept, natural products derivatization method (NPDM), was introduced to assess the influence of natural products on the discovery of targeted anticancer... 
New molecular entities | Natural products derivatization method | Targeted anticancer agents | RAPAMYCIN | HISTONE DEACETYLASE INHIBITOR | CHEMISTRY, MEDICINAL | MECHANISM | BIOCHEMISTRY & MOLECULAR BIOLOGY | CHEMISTRY, ORGANIC | COPANLISIB | DISCOVERY | PATHWAY | VOLASERTIB | TUBULIN | BINDING | PHASE-2 TRIAL
Journal Article
Blood Reviews, ISSN 0268-960X, 05/2019, Volume 35, pp. 68 - 80
Follicular lymphoma (FL) is the most common indolent lymphoma. Therapeutic advances in the past decade have improved its prognosis, but some questions remain... 
Obinutuzumab | Copanlisib | Lenalidomide | CAR T-cell | Follicular lymphoma | Stem cell transplantation | Gene expression | Duvelisib | Localized | Transplantation | Lymphomas | Angiogenesis inhibitors | T cells | Stem cells
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 02/2018, Volume 118, Issue 4, pp. 462 - 470
Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant PI3K-alpha/delta activity that has demonstrated... 
biliary tract cancer | BAY 80-6946 | GENE | ONCOLOGY | copanlisib | phase Ib trial | PATHWAY | gemcitabine | INHIBITORS | cisplatin | CARCINOMA | Biliary tract | Tensin | Gemcitabine | Homology | Nausea | Pharmacology | Patients | Cisplatin | 1-Phosphatidylinositol 3-kinase | Signal transduction | Signaling | Hyperglycemia | Safety management | Biomarkers | In vivo methods and tests | Safety | Mutation | Pharmacokinetics | Cancer | Tumors | Peritoneum | Clinical Study
Journal Article
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, ISSN 0027-8424, 11/2019, Volume 116, Issue 45, pp. 22730 - 22736
Journal Article
EXPERT OPINION ON INVESTIGATIONAL DRUGS, ISSN 1354-3784, 2017, Volume 26, Issue 11, pp. 1267 - 1279
Journal Article
BMC Cancer, ISSN 1471-2407, 10/2019, Volume 19, Issue 1, pp. 1 - 11
The phosphoinositol 3-kinase (PI3K) pathway is associated with poor prognosis of hematologic malignancies, providing a strong rationale for the use of PI3K... 
Care and treatment | Cellular signal transduction | Lymphomas | Research | Analysis | Interleukin-6 | Copanlisib | PI3K | Duvelisib | Drug resistance | Lymphoma | IL-6
Journal Article
Nature Communications, ISSN 2041-1723, 03/2017, Volume 8, Issue 1, p. 14687
Journal Article